Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

• Published in: Journal of global antimicrobial resistance. Vol. 25; pp. 346 - 350
• Main Authors: Zhanel, George G., Dhami, Rita, Baxter, Melanie, Kosar, Justin, Cervera, Carlos, Irfan, Neal, Zvonar, Rosemary, Borgia, Sergio, Tessier, Jean-Francois, Dow, Gordon, Ariano, Robert, Dube, Maxime, Savoie, Michel, Bassetti, Matteo, Walkty, Andrew, Karlowsky, James A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2021; Elsevier
• Subjects: Adverse effect; Bacteraemia; Ceftolozane/tazobactam; CLEAR; Efficacy; Pneumonia; Ceftolozane/tazobactam; Efficacy; Bacteraemia; Pneumonia; Adverse effect; CLEAR; adverse effects; ceftolozane/tazobactam; pneumonia; efficacy; bacteremia

•Use of ceftolozane/tazobactam (C/T) in Canadian patients using data captured by the CLEAR registry.•C/T is used as directed therapy to treat a variety of severe infections caused multidrug-resistant Pseudomonas aeruginosa.•C/T is commonly used combined with other antimicrobials, with relatively hig...